Abstract 2300: Pesticides and primary liver cancer: A systematic review and meta-analysis

Author(s):  
Hamdi Abdi ◽  
Jennifer Lee ◽  
Gary Ellison ◽  
Gabriel Lai ◽  
Tram Lam
2019 ◽  
Vol 71 (8) ◽  
pp. 1365-1373 ◽  
Author(s):  
Kim Tu Tran ◽  
Helen G. Coleman ◽  
Robert Stephen McCain ◽  
Chris R. Cardwell

2021 ◽  
Author(s):  
Dong Shen ◽  
◽  
Zhuang Xiong ◽  
Yangyang Liu ◽  
Yan Leng ◽  
...  

Review question / Objective: The aim of this systematic review is to valuate the efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of primary liver cancer inform clinical practice. To this end, the proposed systematic review will address the following question: Which is the best choice to effective in improving The short-term curative effect is effective, the quality of life is stable, and the survival rate of patients is six months/one year in patients with primary liver cancer, acupuncture combined with Chinese herbal medicine or the best supportive treatment? Information sources: We will search the following databases: PubMed, Web of Science, Embase, AMED, Cochrane Library, CNKI, VIP, CBM, and Wanfang. Additionally, we will manually search all reference lists from relevant systematic reviews to find other eligible studies. We will exclude all conference records, reviews, meta-analyses, newspapers, guides, letters and other documents. When the full text or the required information in the analysis process was missing, the author of the studies was contacted for data.


2021 ◽  
Author(s):  
Dong Shen ◽  
◽  
Zhuang Xiong ◽  
Yangyang Liu ◽  
Yan Leng ◽  
...  

The aim of this systematic review is to compare Chinese herbal medicine combined with Sorafenib in terms of efficacy and acceptability in the primary liver cancer to better inform clinical practice. To this end, the proposed systematic review will address the following question: Which is the best choice to reduce Efficacy and safety in Patients with primary liver cancer, Chinese herbal medicine combined with Sorafenib or Sorafenib.this systematic review and meta-analysis will evaluate the efficacy and Sorafenib combined with Chinese herbal medicine in the treatment of PLC. Information sources: We will search the following databases from inception up to September 8, 2021: PubMed, Web of Science, Embase, AMED, Cochrane Library, CNKI, VIP, CBM, and Wanfang. There will be no restrictions regarding publication date or language. We will apply a combination of medical keywords and words, including "Sorafenib", "Chinese herbal medicine" and "primary liver cancer". Additionally, we will manually search all reference lists from relevant systematic reviews to find other eligible studies.


2021 ◽  
Vol 27 (1) ◽  
pp. 157-174
Author(s):  
Won Sohn ◽  
Hyun Woong Lee ◽  
Sangheun Lee ◽  
Jin Hong Lim ◽  
Min Woo Lee ◽  
...  

Background/Aims: In this systematic review and meta-analysis, we aimed to clarify the effect of obesity on the occurrence of and mortality from primary liver cancer.Methods: This study was conducted using a systematic literature search of MEDLINE, EMBASE, and the Cochrane Library until November 2018 using the primary keywords “obesity,” “overweight,” “body mass index (BMI),” “body weight,” “liver,” “cancer,” “hepatocellular carcinoma,” “liver cancer,” “risk,” and “mortality.” Studies assessing the relationship between BMI and occurrence of or mortality from primary liver cancer in prospective cohorts and those reporting hazard ratios (HRs) or data that allow HR estimation were included.Results: A total of 28 prospective cohort studies with 8,135,906 subjects were included in the final analysis. These included 22 studies with 6,059,561 subjects for cancer occurrence and seven studies with 2,077,425 subjects for cancerrelated mortality. In the meta-analysis, an increase in BMI was associated with the occurrence of primary liver cancer (HR, 1.69; 95% confidence interval, 1.50–1.90, I<sup>2</sup>=56%). A BMI-dependent increase in the risk of occurrence of primary liver cancer was reported. HRs were 1.36 (95% CI, 1.02–1.81), 1.77 (95% CI, 1.56–2.01), and 3.08 (95% CI, 1.21–7.86) for BMI >25 kg/m<sup>2</sup>, >30 kg/m<sup>2</sup>, and >35 kg/m<sup>2</sup>, respectively. Furthermore, increased BMI resulted in enhanced liver cancer-related mortality (HR, 1.61; 95% CI, 1.14–2.27, I<sup>2</sup>=80%).Conclusions: High BMI increases liver cancer mortality and occurrence of primary liver cancer. Obesity is an independent risk factor for the occurrence of and mortality from primary liver cancer.


Sign in / Sign up

Export Citation Format

Share Document